| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.19 | 4e-05 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.1 | 0.03 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.097 | 0.04 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.099 | 0.04 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | -0.089 | 0.06 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.09 | 0.06 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.076 | 0.1 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.075 | 0.1 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.069 | 0.2 |